Indaptus Therapeutics Reprices Warrants to $1.75 and Secures Votes for Dilutive Financing

summarizeSummary

Indaptus Therapeutics has significantly reduced the exercise price of over 1.6 million warrants to $1.75 and secured irrevocable voting agreements from holders to ensure approval of its previously announced highly dilutive financing.

check_boxKey Events

• Warrant Repricing

  Over 1.6 million warrants, originally priced between $8.30 and $47.60, had their exercise price reduced to $1.75 per share, close to the current market price.

• Irrevocable Voting Agreement

  In exchange for the repricing, warrant holders granted an irrevocable proxy to an officer to vote their shares in favor of all proposals at the upcoming special stockholder meeting.

• Secures Dilutive Financing

  These actions are directly aimed at ensuring shareholder approval for the previously announced highly dilutive $6.0 million financing and related board changes.

auto_awesomeAnalysis

This DEFA14A filing details critical actions taken by Indaptus Therapeutics to ensure the passage of its proposed $6.0 million dilutive financing, which was previously disclosed in a DEF 14A on January 21, 2026. The company repriced over 1.6 million outstanding warrants, originally issued at prices ranging from $8.30 to $47.60, down to $1.75 per share. This substantial reduction in exercise price, close to the current market price, incentivizes warrant holders. In exchange for this repricing, these holders have granted an irrevocable proxy to an officer to vote their shares in favor of all proposals at the upcoming special stockholder meeting on February 26, 2026. This move, while securing necessary votes for the financing, represents a significant concession and potential future dilution for existing shareholders, further solidifying the negative implications of the overall financing strategy.